0.51
0.51 (0%)
As of Apr 17, 2025
Invivyd, Inc. [IVVD]
Source:
Company Overview
Invivyd, Inc. is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. PEMGARDA™ (pemivibart) is our first monoclonal antibody (“mAb”) to receive regulatory authorization and was designed to keep pace with SARS-CoV-2 viral evolution.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | (781) 819-0080 |
| Industry | |
| CEO | David Hering, M.B.A. |
| Website | invivyd.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $25.4 |
| Operating Profit | $-176.9 |
| Net Income | $-169.9 |
| Net Cash | $-131.3 |
Profit Ratios
| Gross Margin | $23.8 |
| Operating Margin | -696.8 |
| Profit as % of Revenues | -14% |
| Profit as % of Assets | -94.8% |
| Profit as % of Stockholder Equity | -251.6% |
Management Effectiveness
| Return on Equity | -251.6% |
| Return on Assets | -131.2% |
| Turnover Ratio | 14.2% |
| EBITA | $-176.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $129.5 |
| Total Liabilities | $62 |
| Operating Cash Flow | $-170.5 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $39.3 |
